Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
NCT05797246Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2023
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in recurrent respiratory papillomatosis (RRP), sponsored by National Cancer Institute. Started Aug 2023; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT05797246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05797246.